CoChat

ACE Inhibition Is Renoprotective among Obese Patients with Proteinuria

Open access
Mallamaci, Francesca, Ruggenenti, Piero, Perna, Annalisa, Leonardis, Daniela, Tripepi, Rocco, Tripepi, Giovanni, Remuzzi, Giuseppe, Zoccali, Carmine · 2011 · Journal of the American Society of Nephrology
Cited by 157

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Obesity may increase the risk for progression of CKD, but the effect of established renoprotective treatments in overweight and obese patients with CKD is unknown. In this post hoc analysis of the Ramipril Efficacy In Nephropathy (REIN) trial, we evaluated whether being overweight or obese influences the incidence rate of renal events and affects the response to ramipril. Of the 337 trial participants with known body mass index (BMI), 105 (31.1%) were overweight and 49 (14.5%) were obese. Among placebo-treated patients, the incidence rate of ESRD was substantially higher in obese patients than overweight patients (24 versus 11 events/100 person-years) or than those with normal BMI (10 events/100 person-years); we observed a similar pattern for the combined endpoint of ESRD or doubling of serum creatinine. Ramipril reduced the rate of renal events in all BMI strata, but the effect was higher among the obese (incidence rate reduction of 86% for ESRD and 79% for the combined endpoint) than the overweight (incidence rate reduction of 45 and 48%, respectively) or those with normal BMI (incidence rate reduction of 42 and 45%, respectively). We confirmed this interaction between BMI and the efficacy of ramipril in analyses that adjusted for potential confounders, and we observed a similar effect modification for 24-hour protein excretion. In summary, obesity predicts a higher incidence of renal events, but treatment with ramipril can essentially abolish this risk excess. Furthermore, the reduction in risk conferred by ramipril is larger among obese than nonobese patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2010090969

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 157

Metadata

Authors
Mallamaci, F., Ruggenenti, P., Perna, A., Leonardis, D., Tripepi, R., Tripepi, G., Remuzzi, G., & Zoccali, C.
Venue
Journal of the American Society of Nephrology
Published
2011-06
Volume
22
Issue
6
Pages
1122-1128
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2144135174
Cited by
157
References
3
FWCI
7.67
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ACE Inhibition Is Renoprotective among Obese Patients with Proteinuria. https://app.cochat.ai/papers/10.1681/asn.2010090969
The paper
Mallamaci, F., Ruggenenti, P., Perna, A., Leonardis, D., Tripepi, R., Tripepi, G., Remuzzi, G., & Zoccali, C. (2011). ACE Inhibition Is Renoprotective among Obese Patients with Proteinuria. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2010090969

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.